Provided by Tiger Fintech (Singapore) Pte. Ltd.

Stoke Therapeutics, Inc.

8.60
+0.49006.04%
Post-market: 8.600.00000.00%18:17 EDT
Volume:876.96K
Turnover:7.50M
Market Cap:455.52M
PE:-4.16
High:8.72
Open:8.18
Low:8.18
Close:8.11
Loading ...

Company Profile

Company Name:
Stoke Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2014
Employees:
110
Office Location:
45 Wiggins Avenue,Bedford,Massachusetts,United States
Zip Code:
01730
Fax:
- -
Introduction:
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.

Directors

Name
Position
Edward M. Kaye
Chief Executive Officer and Director
Adrian R. Krainer
Director
Arthur A. Levin
Director
Arthur O. Tzianabos
Director
Jennifer C. Burstein
Director
Samuel W. Hall
Director
Seth L. Harrison
Director

Shareholders

Name
Position
Edward M. Kaye
Chief Executive Officer and Director
Huw M. Nash
Chief Operating Officer and Chief Business Officer
Stephen J. Tulipano
Chief Financial Officer
Barry S. Ticho
Chief Medical Officer
Gene Liau
Executive Vice President, Head of Research and Preclinical Development